Prognostic value of NT-proBNP for myocardial recovery in peripartum cardiomyopathy (PPCM)

• DOI: 10.1007/s00392-021-01808-z
• Publication Date: 2021-02-09T09:14:00Z
• Authors: J. Hoevelmann; E. Muller; F. Azibani; S. Kraus; J. Cirota; O. Briton; M. Ntsekhe; N. A. B. Ntusi; K. Sliwa; C. A. Viljoen
• Keywords: Adult; Systole; 610; Heart failure; 03 medical and health sciences; 0302 clinical medicine; Diastole; Predictive Value of Tests; Pregnancy; Natriuretic Peptide, Brain; Peripartum Period; Humans; Risk stratification; ddc:610; Original Paper; Peripartum cardiomyopathy; Stroke Volume; Prognosis; Peptide Fragments; 3. Good health; NT-proBNP; Female [MeSH] ; Heart failure ; Adult [MeSH] ; Biomarkers/blood [MeSH] ; Humans [MeSH] ; Natriuretic Peptide, Brain/blood [MeSH] ; Peripartum cardiomyopathy ; Predictive Value of Tests [MeSH] ; Systole [MeSH] ; Peripartum Period [MeSH] ; Left ventricular recovery ; Cardiomyopathies/physiopathology [MeSH] ; Peptide Fragments/blood [MeSH] ; Risk stratification ; Original Paper ; Prognosis [MeSH] ; Stroke Volume [MeSH] ; Cardiomyopathies/blood [MeSH] ; Diastole [MeSH] ; Pregnancy [MeSH] ; NT-proBNP; Left ventricular recovery; Female; Cardiomyopathies; Biomarkers

Abstract Introduction Peripartum cardiomyopathy (PPCM) is an important cause of pregnancy-associated heart failure worldwide. Although a significant number of women recover their left ventricular (LV) function within 12 months, some remain with persistently reduced systolic function.

Methods Knowledge gaps exist on predictors of myocardial recovery in PPCM. N-terminal pro-brain natriuretic peptide (NT-proBNP) is the only clinically established biomarker with diagnostic value in PPCM. We aimed to establish whether NT-proBNP could serve as a predictor of LV recovery in PPCM, as measured by LV end-diastolic volume (LVEDD) and LV ejection fraction (LVEF).

Results This study of 35 women with PPCM (mean age 30.0 ± 5.9 years) had a median NT-proBNP of 834.7 pg/ml (IQR 571.2–1840.5) at baseline. Within the first year of follow-up, 51.4% of the cohort recovered their LV dimensions (LVEDD < 55 mm) and systolic function (LVEF > 50%). Women without LV recovery presented with higher NT-proBNP at baseline. Multivariable regression analyses demonstrated that NT-proBNP of ≥ 900 pg/ml at the time of diagnosis was predictive of failure to recover LVEDD (OR 0.22, 95% CI 0.05–0.95, P = 0.043) or LVEF (OR 0.20 [95% CI 0.04–0.89], p = 0.035) at follow-up.

Conclusions We have demonstrated that NT-proBNP has a prognostic value in predicting LV recovery of patients with PPCM. Patients with NT-proBNP of ≥ 900 pg/ml were less likely to show any improvement in LVEF or LVEDD. Our findings have implications for clinical practice as patients with higher NT-proBNP might require more aggressive therapy and more intensive follow-up. Point-of-care NT-proBNP for diagnosis and risk stratification warrants further investigation.